China Heparin Industry Report, 2014-2017

  • October 2014
  • -
  • Research In China
  • -
  • 88 pages

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs raised in China could manufacture 27.9 trillion units of heparin crude products. And in H1 2014, the live hogs in China may produce 14.09 trillion units of heparin crude products, up 5.6% on a year-on-year basis.

In 2011-2013, affected by the economic downturn in Europe and America, the global heparin preparations market continued to drop, with the sales volume of main heparin preparations brands virtually presenting decline, thus dragging down the exports of China’s heparin products. In 2013, China exported approximately 13.68 trillion units of heparin and its salts, falling 5.9% year on year, and the figure edged down 0.6% from a year earlier to around 9.32 trillion units in Jan.-Aug. 2014.

The major global heparin API suppliers, including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma, and Changshan Biochemical Pharmaceutical, have been among the top 4 heparin exporters in China for many years, together accounting for over 60% of China’s total heparin exports. In response to the impact from international markets, enterprises are stepping up efforts to figure out the solutions, with Hepalink expanding its market share of heparin crude products via M&As overseas. By contrast, the enterprises like Qianhong Bio-pharma, Dongcheng Biochemicals, and Changshan Biochemical Pharmaceutical have accelerated the R&D into and production of low molecular weight heparin preparations. And Nanjing King-friend is aggressively seeking to expand capacity through IPO.

Although the leading heparin enterprises planned to increase capacity and improve the heparin industry chain a few years ago, yet quite a few heparin API projects that had been scheduled to go into operation in 2014 were delayed successively due to depressed market demand or improved technical standards, these projects including Dongcheng Biochemicals’ 32t/a Crude Heparin Sodium Project and Qianhong Bio-pharma’s Heparin API and Preparations Expansion Project.

In terms of the proposed/ongoing projects, however, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China’s total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand.

Given that America's economy showed signs of recovery and the European economy did not continue to deteriorate, we foresee that the market size of the global heparin API and preparation market will bounce back in 2014-2017, when China’s heparin industry, heparin API in particular, will see an improved degree of prosperity, thus further releasing new capacity.

China Heparin Industry Report, 2014-2017 mainly deals with the followings:
Global heparin supply & demand, competitive landscape and forecast, etc.;
Development, access barriers, supply & demand, competitive landscape, import & export, and development forecast, etc. of China heparin API industry;
Development, supply & demand, competitive landscape and development forecast, etc. of China heparin preparations industry;
Operation, Heparin Business, development prospect, etc. of 7 heparin enterprises, including Hepalink, Nanjing King-friend, Qianhong Bio-pharma, Dongcheng Biochemicals, as well as Changshan Biochemical Pharmaceutical.

Table Of Contents

1. Overview of Heparin Industry
1.1 Definition and Classification
1.2 Industry Chain

2. Operating Environment of Heparin Industry in China
2.1 Access Barriers
2.1.1 Related Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Global Market Supply and Demand
2.3 Global Market Competition
2.4 Global Market Forecast
3. Development of Heparin API Industry in China
3.1 Status quo
3.2 Supply and Demand
3.3 Competitive Landscape
3.4 Import and Export
3.4.1 Export
3.4.2 Import
3.5 Prospect and Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Low Molecular Heparin Preparation
4.2.1 Low Molecular Weight Heparin Calcium Preparation
4.2.2 Low Molecular Weight Heparin Sodium Preparation
4.3 Unfractionated Heparin Preparation
4.4 Prospect and Forecast

5. Key Heparin Enterprises in China
5.1 Hepalink
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 RandD and Investment
5.1.6 Major Clients
5.1.7 Heparin Business
5.1.8 Prospect and Forecast

5.2 Qianhong Bio-pharma
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 RandD and Investment
5.2.6 Major Clients
5.2.7 Heparin Business
5.2.8 Prospect and Forecast

5.3 Dongcheng Biochemicals
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 RandD and Investment
5.3.6 Major Clients
5.3.7 Heparin Business
5.3.8 Prospect and Forecast

5.4 Changshan Biochemical Pharmaceutical
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 RandD and Investment
5.4.6 Major Clients
5.4.7 Heparin Business
5.4.8 Prospect and Forecast

5.5 Tianjin Chase Sun Pharmaceutical
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 RandD and Investment
5.5.6 Major Clients
5.5.7 Heparin Business
5.5.8 Prospect and Forecast

5.6 Nanjing King-friend
5.6.1 Profile
5.6.2 Operation and Prospect

5.7 Wanbang Biopharmaceuticals
5.7.1 Profile
5.7.2 Development
5.7.3 Operation
5.7.4 Heparin Business


Companies Mentioned
Hepalink
Qianhong Bio-pharma
Dongcheng Biochemicals
Changshan Biochemical Pharmaceutical
Tianjin Chase Sun Pharmaceutical
Nanjing King-friend
Wanbang Biopharmaceuticals

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Drug Discovery and Development Industry: Critical Outcome Technologies Inc. – Product Pipeline Review – Q2 2011

Drug Discovery and Development Industry: Critical Outcome Technologies Inc. – Product Pipeline Review – Q2 2011

  • $ 1 500
  • Industry report
  • October 2014
  • by Global Markets Direct

- Product Pipeline Review - Q2 2011” provides a detailed overview on the Critical Outcome Technologies Inc.’s research and development focus. The report includes data on current developmental pipeline, ...

Drug Discovery and Development in United States: Symphogen A/S – Product Pipeline Review – H2 2011

Drug Discovery and Development in United States: Symphogen A/S – Product Pipeline Review – H2 2011

  • $ 1 500
  • Industry report
  • October 2014
  • by Global Markets Direct

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...

Orion Oyj - Product Pipeline Review - 2014

Orion Oyj - Product Pipeline Review - 2014

  • $ 1 500
  • Industry report
  • October 2014
  • by Global Markets Direct

Orion Oyj - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Orion Oyj - Product Pipeline Review - 2014', provides an overview of the Orion Oyj's pharmaceutical research and development ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.